Neurocrine Biosciences Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
97 / 1361
Position in country
1639 / 14179
Return on Assets, %
8.4
-40.3
Net income margin, %
28.6
-180
EBITDA margin, %
30.2
-168.2
Debt to Equity, %
7.6
3.2
Intangible assets and goodwill, %
1
0.2
Revenue CAGR 3Y, %
21.7
12.5
Total Equity change 1Y, %
30.6
-9
Revenue Y, % chg
26.7
0
P/E
55.3
31
P/BV
5.9
1.8
P/S
7.1
10.3
EV/S
6.7
7.5
EV/EBITDA
30.4
-1.6
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
12.8
131.1
Forward P/E
26.1
21.4
Expected dividend per share
0
0
Payout Ratio, %
0
0
Competitors
Ranks
-
Neurocrine Biosciences Inc
00%
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
13544.1
Ticker
NBIX.O
ISIN
US64125C1099
IPO date
1996-05-23
Availability on Russian exchanges
Yes
Reporting for
2024-02-09
Date fact. publication of reports
2023-12-31
Company Description
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: